Astellas Pharma Inc: all 983 studies

Page 2 of 10. Open to participants first (40), then studies with results posted, then the rest; newest registration first within each.

• A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)CompletedNCT02656173Phase 4Results posted
• A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaCompletedNCT02639182Phase 2Results posted
• A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsTerminatedNCT02588261Phase 3Results posted
• Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 TrialCompletedNCT02561455Phase 1/2Results posted
• A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular CarcinomaCompletedNCT02528643Phase 2Results posted
• A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02495233Phase 1/2Results posted
• A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel TreatmentTerminatedNCT02441517Phase 4Results posted
• A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationCompletedNCT02421939Phase 3Results posted
• A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)CompletedNCT02397954Phase 2Results posted
• A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)TerminatedNCT02387957Phase 2Results posted
• Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive EpisodesCompletedNCT02362412Phase 3Results posted
• A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.CompletedNCT02310321Phase 1/2Results posted
• A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDsCompletedNCT02308163Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) TreatmentCompletedNCT02305849Phase 3Results posted
• An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer ParticipantsCompletedNCT02294461Phase 3Results posted
• Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.CompletedNCT02294396Phase 4Results posted
• A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide AloneCompletedNCT02288247Phase 3Results posted
• Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable DialysisCompletedNCT02278341Phase 3Results posted
• A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)CompletedNCT02218372Phase 3Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)CompletedNCT02216214Phase 4Results posted
• Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMDTerminatedNCT02214628Phase 2Results posted
• A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)CompletedNCT02138747Phase 4Results posted
• Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a TransplantCompletedNCT02118896Phase 3Results posted
• A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate CancerCompletedNCT02116582Phase 4Results posted
• A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast CancerCompletedNCT02091960Phase 2Results posted
• A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive BladderCompletedNCT02045862Phase 3Results posted
• Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin AlfaCompletedNCT02021318Phase 3Results posted
• Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02014558Phase 1/2Results posted
• A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)CompletedNCT01981954Phase 3Results posted
• A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With EnzalutamideCompletedNCT01977651Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive DonorCompletedNCT01974206Phase 2Results posted
• This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive BladderCompletedNCT01972841Phase 3Results posted
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01944839Phase 3Results posted
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01940900Phase 3Results posted
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® MonotherapyTerminatedNCT01940887Phase 3Results posted
• A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)CompletedNCT01908829Phase 3Results posted
• Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring DialysisCompletedNCT01887600Phase 3Results posted
• A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)CompletedNCT01877655Phase 3Results posted
• A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder PatientsCompletedNCT01745094Phase 4Results posted
• Long-term Study of FK949E in Elderly Bipolar Disorder PatientsCompletedNCT01737268Phase 3Results posted
• A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive EpisodesCompletedNCT01725308Phase 2/3Results posted
• Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive DisorderCompletedNCT01725282Phase 2Results posted
• A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076CompletedNCT01655069Phase 3Results posted
• A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsCompletedNCT01650194Phase 2Results posted
• A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015KCompletedNCT01638013Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.CompletedNCT01638000Phase 3Results posted
• A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)CompletedNCT01618669Phase 3Results posted
• A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active DrugCompletedNCT01565707Phase 3Results posted
• A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor OveractivityCompletedNCT01565694Phase 3Results posted
• A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100CompletedNCT01534052Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)CompletedNCT01533428Phase 3Results posted
• Efficacy Confirmation Study of CDP870 in Early Rheumatoid ArthritisCompletedNCT01451203Phase 3Results posted
• A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical ProstatectomyCompletedNCT01371994Phase 4Results posted
• A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive BladderCompletedNCT01340027Phase 2Results posted
• A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)CompletedNCT01334918Phase 2Results posted
• A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone TherapyCompletedNCT01302041Phase 2Results posted
• A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate CancerCompletedNCT01288911Phase 2Results posted
• Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205TerminatedNCT01247922Phase 2Results posted
• A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental AbilityCompletedNCT01126424Phase 4Results posted
• Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.CompletedNCT01093534Phase 4Results posted
• A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular DegenerationCompletedNCT01089517Phase 2Results posted
• Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric EpendymomaTerminatedNCT01032070Phase 2Results posted
• Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract SymptomsCompletedNCT01021332Phase 3Results posted
• Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract SymptomsCompletedNCT01018511Phase 3Results posted
• A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00912964Phase 3Results posted
• A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal ImpairmentCompletedNCT00863707Phase 4Results posted
• A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary DiseaseCompletedNCT00862641Phase 4Results posted
• Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) PatientsCompletedNCT00851318Phase 3Results posted
• Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) PatientsCompletedNCT00850343Phase 3Results posted
• Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)CompletedNCT00826280Phase 3Results posted
• Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal CandidiasisTerminatedNCT00815516Phase 3Results posted
• Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00689104Phase 3Results posted
• Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00688688Phase 3Results posted
• A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00662909Phase 3Results posted
• Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis SubjectsCompletedNCT00658606Phase 4Results posted
• Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare FungiCompletedNCT00634049Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant RecipientsCompletedNCT00617604Phase 2Results posted
• Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of LifeCompletedNCT00573508Phase 4Results posted
• A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant RecipientsCompletedNCT00543569Phase 2Results posted
• Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet ObstructionCompletedNCT00507455Phase 2Results posted
• Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)CompletedNCT00431041Phase 4Results posted
• Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida InfectionsCompletedNCT00413218Phase 3Results posted
• Isavuconazole (BAL8557) for Primary Treatment of Invasive AspergillosisCompletedNCT00412893Phase 3Results posted
• A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)CompletedNCT00410514Phase 2Results posted
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsCompletedNCT00373425Phase 3Results posted
• Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLCCompletedNCT00294762Phase 2Results posted
• A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant PatientsCompletedNCT00282568Phase 2Results posted
• A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant PatientsCompletedNCT00282256Phase 2Results posted
• A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant PatientsCompletedNCT00282243Phase 2Results posted
• Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic RegimensCompletedNCT00157014Phase 3Results posted
• Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant RecipientsCompletedNCT00113269Phase 4Results posted
• A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical ProstatectomyCompletedNCT00106392Phase 4Results posted
• Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2CompletedNCT00085839Phase 2Results posted
• Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant RecipientsCompletedNCT00064701Phase 3Results posted
• A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During MenopauseCompletedNCT07455812
• A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy AdultsActive, not recruitingNCT07395024Phase 1
• A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular DegenerationActive, not recruitingNCT06970665Phase 4
• A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through MenopauseCompletedNCT06812754Phase 2
• XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Active, not recruitingNCT06792435Phase 1/2
• A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic AtrophyActive, not recruitingNCT06779773

← Astellas Pharma Inc overview and focus areas